Posted by Michael Wonder on 12 Jun 2024
Pembrolizumab in combination with trastuzumab and chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastro-oesophageal junction adenocarcinoma (final guidance)
12 June 2024 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) in combination with trastuzumab and chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma.
Pembrolizumab, when used in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy is not recommended for the first-line treatment of adults with locally advanced unresectable or metastatic HER2 positive gastric or gastro-oesophageal junction adenocarcinoma whose tumours express PD‑L1 with a combined positive score of 1 or more.
